Below are the top small-cap diagnostic substances stocks on the NYSE and the NASDAQ in terms of earnings estimate for the next year.
Neogen NEOG is likely to earn $1.30 per share in the next year ending May, 2014. Neogen's PEG ratio is 2.06.
Abaxis ABAX may earn $1.11 per share in the next year ending March, 2014. Abaxis' trailing-twelve-month operating margin is 12.95%.
Trinity Biotech plc TRIB is projected to earn $0.92 per share for the next year ending December, 2013. Trinity Biotech's trailing-twelve-month revenue is $80.67 million.
Meridian Bioscience VIVO is expected to earn $0.88 per share over the next year ending September, 2013. Meridian Bioscience's trailing-twelve-month ROE is 22.58%.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in